Regenxbio (RGNX) Cash from Financing Activities (2014 - 2025)

Regenxbio's Cash from Financing Activities history runs 12 years deep, the most recent figure standing at -$9.6 million for Q4 2025.

• In Q4 2025, Cash from Financing Activities fell 23.82% year-over-year to -$9.6 million; the TTM figure through Dec 2025 stood at $116.8 million (up 25.99% YoY), while the FY2025 annual figure was $116.8 million, up 25.99% from the prior year.
• Cash from Financing Activities for Q4 2025 stood at -$9.6 million, down from -$7.1 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $211.3 million in Q1 2021, with the low at -$12.0 million in Q4 2023.
• The 5-year median for Cash from Financing Activities is -$7.3 million (2021), against an average of $17.0 million.
• Peak annual rise in Cash from Financing Activities reached 7552.52% in 2021, while the deepest fall reached 436.27% in 2021.
• Regenxbio's Cash from Financing Activities stood at -$7.6 million in 2021, then dropped by 17.12% to -$8.9 million in 2022, then sank by 34.1% to -$12.0 million in 2023, then jumped by 35.3% to -$7.7 million in 2024, then slipped by 23.82% to -$9.6 million in 2025.
• Business Quant data shows RGNX's Cash from Financing Activities at -$9.6 million in Q4 2025, -$7.1 million in Q3 2025, and $139.2 million in Q2 2025.